Gerlai Julia, Gerlai Robert
Neuroscience Discovery Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Physiol Behav. 2003 Aug;79(3):461-70. doi: 10.1016/s0031-9384(03)00165-3.
Autism has been becoming the focus of attention as its apparently increasing prevalence is better appreciated. According to some estimates, the frequency of children with autistic spectrum disorder (ASD) can be as high as 1 in 150. The diagnosis can be made as early as 2 years of age, and autistic patients often have a normal life span. Thus, in terms of the number of "patient years," ASD represents a market that is as large as that of the biggest neurological indication, Alzheimer's disease. Despite the clear unmet medical need, no effective treatment is available. This may be because the mechanism of ASD is not understood. The aim of the present paper is to review recent advances in autism research and to discuss some of the most stressing problems mainly from a preclinical research standpoint. We hope to draw attention to the need to study this devastating disease that places an enormous burden on the society in general and the relatives and caregivers of autistic patients in particular.
随着自闭症明显上升的患病率得到更好的认识,它已成为人们关注的焦点。据一些估计,自闭症谱系障碍(ASD)儿童的发病率高达1/150。该诊断最早可在2岁时做出,且自闭症患者通常寿命正常。因此,就“患者年数”而言,ASD所代表的市场规模与最大的神经学适应症——阿尔茨海默病相当。尽管存在明确未被满足的医疗需求,但尚无有效的治疗方法。这可能是因为ASD的发病机制尚不清楚。本文的目的是回顾自闭症研究的最新进展,并主要从临床前研究的角度讨论一些最突出的问题。我们希望引起人们对研究这种给整个社会,尤其是自闭症患者的亲属和照料者带来巨大负担的毁灭性疾病的必要性的关注。